<div id="readability-page-1"><p>Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares hit a new 52-week high on Thursday . The company traded as high as $19.46 and last traded at $19.50, with a volume of 3758 shares changing hands. The stock had previously closed at $17.92.</p><div><p><span></span><span>Get <strong>Pharming Group</strong> alerts:</span></p></div><h2>Wall Street Analyst Weigh In</h2><p>Several equities research analysts recently commented on PHAR shares. Wall Street Zen raised Pharming Group to a &#34;strong-buy&#34; rating in a research note on Saturday, December 27th. Weiss Ratings  restated a &#34;hold (c-)&#34; rating on shares of Pharming Group in a report on Monday, December 22nd. Finally, Zacks Research cut shares of Pharming Group from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, January 1st. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $38.00.</p><p><b>Check Out Our Latest Analysis on Pharming Group</b></p><h2>Pharming Group Price Performance</h2><p>The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $1.39 billion and a price-to-earnings ratio of -1,970.03. The company's fifty day moving average is $17.26 and its two-hundred day moving average is $14.60. </p><p>Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.05. The company had revenue of $97.30 million during the quarter, compared to analyst estimates of $98.22 million. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%.  Equities research analysts anticipate that  Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year. </p><h2>Institutional Trading of Pharming Group</h2><p>A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new stake in  Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 2,979 shares of the company's stock, valued at approximately $32,000. Institutional investors own  0.03% of the company's stock. </p><h2>About Pharming Group</h2> (Get Free Report)<p>Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.  </p><p>The company's lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Pharming Group</li><li>The Government Prints Trillions. Silver Supply Is Limited.</li><li>Your Signature Is Missing – Act Before It’s Too Late</li><li>Wall Street Alert: Buy AES</li><li>Trump Did WHAT??</li><li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pharming Group Right Now?</h2><p>Before you consider Pharming Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.</p><p>While Pharming Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

<p>Pharming Group (NASDAQ:PHAR) reached a new 52-week high of $19.50, up from a previous close of $17.92. Analysts have mixed ratings, with two recommending a Buy and two a Hold, leading to a consensus rating of "Moderate Buy" and a target price of $38.00. The company reported $0.10 EPS, exceeding estimates, with revenue of $97.30 million. Institutional ownership is low at 0.03%. Pharming focuses on innovative therapies for rare diseases, with its lead product RUCONEST approved in multiple markets.</p>

Pharming Group (NASDAQ:PHAR) Sets New 12-Month High - What's Next?